Stock Analysis
Data Source: SEC EDGAR 13F
Updated Hourly

Rein Therapeutics Inc (RNTX)

44 + Investors. Track Smart Money conviction in RNTX. See who's accumulating, reducing, or initiating positions.

Current Price
-- USD
Analyst Target
-- (0 analysts)
Upside
0.00%
Net Flow Q/Q
↓ -1
Streak
1Q ▼
Buyers last Q
60%

Smart Money Signals — RNTX

Based on 44 hedge funds · latest filing: 2026 Q1 · updated quarterly

📉

Selling streak — 1 quarter in a row

last 6Q
For 1 consecutive quarter, more hedge funds reduced or closed their RNTX positions than added to them. Sustained institutional selling is a meaningful warning sign — these are professionals with deep research teams collectively deciding to exit.
🏔️

At the ownership peak (98% of max)

98% of all-time peak
44 hedge funds hold RNTX right now — the highest count in 3.0 years. When ownership is this concentrated, any bad news can trigger a chain reaction: one big fund sells, others follow. This is a classic 'crowded trade' — high popularity doesn't equal safety.
🚀

Fast accumulation — +22% more funds vs a year ago

fund count last 6Q
+8 new funds entered over the past year (+22% YoY). That's a rapid rush of institutional money. Fast accumulation often signals a major thesis — but it also means the stock could fall quickly if that thesis breaks.
🟢

More buyers than sellers — 60% buying

24 buying16 selling
Last quarter: 24 funds were net buyers (10 opened a brand new position + 14 added to an existing one). Only 16 were sellers (5 trimmed + 11 sold completely). A clear majority buying is a strong confirmation signal.
➡️

Steady new buyers — ~10 new funds per quarter

new funds entering per quarter
Funds opening this position for the first time: 4 → 6 → 12 → 10. A stable flow of new institutional buyers suggests ongoing interest without signs of either acceleration or slowdown.
📌

Mixed — 25% long-term, 39% new

■ 25% conviction (2yr+) ■ 36% medium ■ 39% new
Of the 44 current holders: 11 (25%) held >2 years, 16 held 1–2 years, and 17 entered in the last year. A mixed base — the stock has long-term believers but also recent buyers who haven't been tested by a downturn yet.
➡️

Steady discovery — ~10 new funds/quarter

9 → 4 → 6 → 12 → 10 new funds/Q
New funds entering each quarter: 4 → 6 → 12 → 10. Consistent flow of new institutional buyers without clear acceleration or slowdown.
📊

Mixed cohorts — 27% veterans, 45% new entrants

■ 27% veterans ■ 27% 1-2yr ■ 45% new
Of 44 current holders: 12 (27%) held 2+ years, 12 held 1–2 years, 20 (45%) entered in the past year. Balanced distribution — some institutional memory, some recent momentum buyers.
📋

Smaller funds dominant — 5% AUM from top-100

5% from top-100 AUM funds
6 of 44 holders rank in the top 100 by AUM, but together hold only 5% of total institutional value. The stock is held primarily by smaller and mid-sized funds.
4.4
out of 10
Moderate Exit Risk
Exit risk score 4.4/10 — some crowding factors present, but no critical concentration. Watch ownership trend over the next 1–2 quarters for direction.

Methodology note: these Smart Money cards use consecutive 13F disclosure snapshots, not trade-by-trade execution data. "Buying", "selling", "new holders", and "trimmed" refer to quarter-over-quarter changes in reported holders, aggregate shares, or disclosed position values between filings. They are useful for ownership regime analysis and crowding, but they do not imply exact trade timing on the filing date.

Institutional Sentiment Summary — RNTX

In 2026 Q1, 24 hedge funds were net buyers of RNTX (10 opened a new position, 14 added to an existing one), while 16 reduced or exited (5 trimmed, 11 sold completely) — a 60% buyer ratio, indicating clear institutional accumulation. Net fund flow last quarter: -1 funds (more exits than new entries). Total institutional holders: 44.

Hedge Fund Ownership: RNTX

How many hedge funds hold RNTX — quarterly history vs. share price
Quarterly hedge fund ownership of RNTX vs. share price

Market Analysis: RNTX

Analyst Price Targets

Avg. Price Target
--

Analyst Recommendations

Stock Performance

Real-time

Company Profile: RNTX

-- --

Institutional ownership data sourced from SEC EDGAR Form 13F-HR filings.

Is It Too Late to Buy Rein Therapeutics Inc (RNTX) Based on Hedge Fund 13F Filings?

Signal Freshness measures how much RNTX has moved relative to its sector benchmark (XLV) since the 2026 Q1 13F filing. A stock that has barely outrun its sector is still a relatively fresh entry point — the fund's thesis has not yet been priced in by the broader market.

Since Quarter End March 31, 2026 · 91d ago
RNTX
-20.0%
XLV
+10.1%

RNTX outperformed XLV by -30.1% since March 31, 2026.

Since 13F Filing Date May 15, 2026 · 46d ago
RNTX
-1.0%
XLV
+11.3%

Since the filing became public, RNTX outperformed XLV by -12.3% .

Interpretation: The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference. Learn more →

Smart Money Signal ?
Limited Smart Money Interest

No strong consensus or elite conviction detected among institutional holders.

4 top-rated funds 1 high-conviction
Consensus
3.0
/ 10
breadth
×
Elite
0.8
/ 10
conviction
Hedge Fund Positioning: RNTX
44 + Investors

Track Smart Money conviction in RNTX. See who's accumulating, reducing, or initiating positions.

Metric All 13F Filers (2026 Q1) Prior (2025 Q4) Change
Funds Holding 44 45 -2.22%
13F Shares 11M 11M 5.37%
Total Value $15M $15M -3.87%
New Positions 10 12 -2
Increased Positions 14 14 -
Closed Positions 11 4 +7
Reduced Positions 5 5 -
Total Calls 0 0 -
Total Puts 0 0 -
PUT/CALL Ratio 0.0 0.0 Bullish

Statistics: RNTX

View More

Valuation Measures Data as of: --

Market Cap --
Enterprise Value --
Trailing P/E --
Forward P/E --
PEG Ratio (5yr expected) --
Price/Sales (ttm) --
Price/Book (mrq) --
Enterprise Value/Revenue --
Enterprise Value/EBITDA --
Beta (5Y Monthly) --
Short Ratio (Days to Cover) --
Short % of Float --

Financial Highlights

Profitability
Profit Margin --
Return on Assets (ttm) --
Return on Equity (ttm) --
Income Statement & Cash Flow
Revenue (ttm) --
Net Income Avi to Common (ttm) --
Diluted EPS (ttm) --
Total Cash (mrq) --
Total Debt/Equity (mrq) --
Levered Free Cash Flow (ttm) --

Institutional Holders (2026 Q1)

44 + investors

Explore institutional interest and hedge fund ownership dynamics. Analyze portfolio weights, new positions, and conviction trends in RNTX. Verified SEC 13F-HR filings.

QUARTER:
Top 25 RNTX holders by conviction (% of portfolio weight) — 2026 Q1 · Source: SEC Form 13F
# Investor % of Portfolio Shares Mkt Value
1 BIOS Capital Management, LP 4.87% 1,982,375 $2.6M
2 Voss Capital, LP 0.30% 4,388,362 $5.7M
3 Cable Car Capital, LP 0.19% 420,000 $546K
4 ABS Direct Equity Fund LLC 0.12% 125,000 $162K
5 Palogic Value Management, L.P. 0.10% 180,000 $234K
6 University of Texas/Texas AM Investment Management Co 0.10% 511,610 $665K
7 Prosight Management, LP 0.09% 411,600 $535K
8 Gagnon Securities LLC 0.07% 239,520 $311K
9 Texas Capital Bank Wealth Management Services Inc 0.02% 273,625 $356K
10 Rock Creek Group LLC 0.02% 125,000 $162K
11 Sigma Planning Corp 0.01% 348,677 $453K
12 Cane Capital Partners, LLC 0.01% 18,000 $23K
13 Senvest Management, LLC 0.01% 230,895 $300K
14 Meridian Wealth Advisors, LLC 0.00% 28,486 $37K
15 Two Sigma Securities, LLC 0.00% 31,713 $41K
16 Sanders Morris Harris LLC 0.00% 20,000 $26K
17 Gleason Group, Inc. 0.00% 22,389 $29K
18 Chicago Partners Investment Group LLC 0.00% 41,048 $77K
19 Exencial Wealth Advisors, LLC 0.00% 30,528 $40K
20 Americana Partners, LLC 0.00% 27,302 $35K
21 XTX Topco Ltd 0.00% 32,924 $43K
22 Ancora Advisors LLC 0.00% 20,000 $26K
23 SteelPeak Wealth, LLC 0.00% 13,000 $17K
24 Jfs Wealth Advisors, LLC 0.00% 1,590 $2K
25 Tower Research Capital LLC (TRC) 0.00% 3,391 $4K
Investor Ownership
History 		% of Portfolio Prev % Rank Conviction Avg Buy Price 13F Score™ 3Y / 7Y Sell Timing Shares Mkt Value Change Change % Source Quarter Filed

Frequently Asked Questions — Rein Therapeutics Inc (RNTX)

What does the Smart Money Trend signal show for RNTX?

Selling streak — 1 quarter in a row: For 1 consecutive quarter, more hedge funds reduced or closed their RNTX positions than added to them. Sustained institutional selling is a meaningful warning sign — these are professionals with deep research teams collectively deciding to exit.

What is the institutional breadth score for RNTX?

More buyers than sellers — 60% buying: Last quarter: 24 funds were net buyers (10 opened a brand new position + 14 added to an existing one). Only 16 were sellers (5 trimmed + 11 sold completely). A clear majority buying is a strong confirmation signal.

What is the fund quality score for RNTX holders?

Smaller funds dominant — 5% AUM from top-100: 6 of 44 holders rank in the top 100 by AUM, but together hold only 5% of total institutional value. The stock is held primarily by smaller and mid-sized funds.

How long have hedge funds held RNTX?

Mixed — 25% long-term, 39% new: Of the 44 current holders: 11 (25%) held >2 years, 16 held 1–2 years, and 17 entered in the last year. A mixed base — the stock has long-term believers but also recent buyers who haven't been tested by a downturn yet.

Is it too late to buy Rein Therapeutics Inc (RNTX) following the 2026 Q1 hedge fund 13F filings?

As of today, RNTX has moved -1.0% since the 2026 Q1 13F filing date (May 15, 2026), compared to +11.3% for the XLV sector ETF — an outperformance of -12.3%. Since the quarter end (March 31, 2026), RNTX has gained -20.0% vs +10.1% for XLV. The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference.

Where does this institutional ownership data come from?

All holdings data is sourced from SEC Form 13F filings, which institutional investment managers with over $100 million in assets are required to submit quarterly. Data is parsed directly from SEC EDGAR.

Disclaimer: The information on this page is for informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Institutional holdings data is sourced from SEC Form 13F filings and reflects positions as of the filing date. Past performance of any fund or portfolio is not indicative of future results. 13Foresight is not a registered investment adviser. Always conduct your own due diligence before making investment decisions.

Full history →